Membrane Bioreactor (MBR) Patents: Leaders & Filing Trends 2026
- Filing has peaked and declined. activity topped out in 2018 at 36 filings and has trended down since, with the flat 2022 midpoint of 18 confirming the slowdown rather than a data artifact.
- The top 5 filers hold 30.5% of the field. 165 of 541 records in scope sit with five assignees, with the leader alone accounting for 54 — well ahead of fifth place at 19.
- Separation-process claims are nearly as dense as water-treatment claims. B01D (filtration/separation) appears on 40.5% of records, meaning membrane and separation hardware claims sit almost as thick as the core wastewater-treatment class.
What the MBR patent record actually shows
Membrane bioreactor systems combine biological treatment with membrane separation, and the patent record reflects that dual identity: nearly every record touches C02F water and wastewater treatment, while a substantial share also claims B01D separation hardware. The search scope defined here pulls 541 records filed or published between 2015 and the mid-2026 cut-off, filtered specifically to documents that address fouling, aeration energy, sludge retention time, flux sustainability or cleaning protocols — the operational problems that determine whether an MBR plant is economical to run.
Filing concentrated early in the window and has since cooled: the peak year was 2018, and the 2022 midpoint shows filings roughly half that peak with no rebound visible through the most recent complete years. Publication lags filing by roughly 18 months, so the final year or two in any trend chart will always look thinner than it eventually turns out to be — that alone does not explain a multi-year decline from a 2018 peak.
Filing trend and technology composition
Two views of the same 541-record scope: how filing volume moved year over year, and how claims distribute across IPC subclasses.
A 2018 peak followed by a flat-to-declining run
Filings ran at 34 in 2017, rose to a peak of 36 in 2018, and by the 2022 midpoint had fallen to 18 — roughly half the peak. There is no later resurgence in the data through the most recent complete filing years; the last year or two in the chart is partial and will fill in somewhat as publications catch up, but the multi-year downward slope from 2018 predates any lag effect.
Water treatment dominates; separation hardware is the strongest secondary claim
C02F (water and wastewater treatment) appears on 97.6% of the 541 records, which is expected given the search scope. The more informative split is beneath that: B01D (separation processes, including filtration) sits at 40.5%, meaning four in ten records also stake a claim on membrane or filtration hardware rather than treatment chemistry alone. Everything else — bioreactor apparatus (C12M), mixing (B01F), fermentation (C12P), catalysis (B01J) and analytical methods (G01N) — sits under 6% each, marking those as thin, contestable branches rather than crowded ones.
Shares are the percentage of the 541 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Membrane Bioreactor (MBR) Systems with Eureka
This page is one run against one query. Ask Eureka your own question about membrane bioreactor (mbr) systems and every answer comes back with the patent numbers behind it.
Try EurekaThe most-cited prior art in this scope
Membrane bioreactor for strengthening membrane fouling control and method thereof (US10442712B2)
Filed by Nanjing University and granted in 2019, this patent describes an MBR configuration built specifically to address fouling control without relying on chemical cleaning agents — the reactor wall, membrane element, collecting and water pipes, vacuum table, suction pump, cleaning unit, air compressor and aeration components are integrated into a single fouling-control architecture. The stated aim is to avoid the operational complexity and secondary pollution risk that chemical-based cleaning protocols introduce.Abstract condensed from the original filing.


| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20060201876A1 | Filtration apparatus comprising a membrane bioreactor and a treatment vessel for digesting organic materials | 155 |
| 2 | US6616843B1 | Submerged membrane bioreactor for treatment of nitrogen containing water | 142 |
| 3 | US20050045557A1 | Method for treating wastewater in a membrane bioreactor to produce a low phosphorus effluent | 131 |
| 4 | US20050194310A1 | Zero excess sludge membrane bioreactor | 130 |
| 5 | US6946073B2 | Method for treating wastewater in a membrane bioreactor to produce a low phosphorus effluent | 97 |
| 6 | US7329344B2 | Grease and scum removal in a filtration apparatus comprising a membrane bioreactor and a treatment vessel for… | 93 |
| 7 | US20070084791A1 | Grease and scum removal in a filtration apparatus comprising a membrane bioreactor and a treatment vessel for… | 74 |
| 8 | US7387723B2 | Filtration apparatus comprising a membrane bioreactor and a treatment vessel for digesting organic materials | 71 |
| 9 | WO2005107929A2 | Filtration apparatus comprising a membrane bioreactor and a treatment vessel for digesting organic materials | 71 |
| 10 | US20080277340A1 | Method for controlling fouling of a membrane filter | 65 |
Citation counts inside a searched corpus favour older filings simply because they have had longer to accumulate citations — read this as a map of influential prior art, not of current commercial importance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for a filing decision
Three read-throughs from the concentration, geography and citation data — useful for deciding where a new filing has room and where it does not.
The top of the field is settled, the rest is a long tail
Five assignees hold 30.5% of all 541 records in scope, and the leader alone holds 54 records against a fifth-place count of 19. Below the top 10 (40.5% combined), the ranking spreads across 100 companies — a long tail of single- or few-filing entrants rather than a second concentrated tier.
Filing has slowed since its 2018 peak
Every one of the recent-year momentum figures available for the leading assignees shows zero filings in the latest tracked year. Combined with the 2018 peak and the flat 2022 midpoint, this points to a field where the largest incumbents have already staked their core claims and are not currently pressing new ones.
Filing is split across US, China and Europe with no single dominant office
The United States leads receiving-office counts at 119, China follows at 97, and the EPO at 81, with WIPO/PCT filings at 59. That spread means clearance searches for a new MBR filing need to cover at least three major jurisdictions rather than one.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to membrane bioreactor (mbr) systems, with the prior art for and against each one.
Who holds the claim space, and where the gate is thin
The leading assignees hold their positions mostly through early, foundational filings rather than sustained recent activity — every top assignee tracked for recent-year momentum shows zero filings in the latest year.
One assignee holds nearly triple the fifth-place count
The leading assignee's 54 records sit well clear of fifth place at 19, a gap that suggests an early, broad filing strategy rather than a race that stayed close among the top few. That gap has held rather than closed, since recent-year filings from the top assignees are flat at zero.
Co-filing is limited and concentrated on a few relationships
Only ten co-assignee pairs appear in the dataset, and the strongest of them link a small number of large filers to individual named inventors or academic partners rather than to other companies. This points to MBR patenting being largely an in-house activity, with joint filings the exception rather than the norm.
The largest incumbents have gone quiet in the most recent filing year
Every one of the six assignees tracked for recent-year momentum shows zero filings in the latest year. Given publication lag, some of this is an artifact of the 2026 cut-off, but the pattern lines up with the broader decline from the 2018 peak rather than contradicting it.
| Assignee | Recent year | YoY |
|---|---|---|
| General Electric Co. | 0 | — |
| Nalco Co. | 0 | — |
| BL Technology Inc. | 0 | — |
| Siemens Water Technologies | 0 | — |
| Evoqua Water Technologies LLC | 0 | — |
| Veolia Water Solutions & Technologies Support SAS | 0 | — |
| Doosan Heavy Industries & Construction Co., Ltd. | 0 | — |
| Alfa Laval Corporate AB | 0 | — |
Where to take this next
The dataset points to specific next steps depending on whether you are clearing a filing, tracking a competitor, or scoping a licensing conversation.
Run a freedom-to-operate check against the top-cited records
The five most-cited records in this scope, several from the same lineage of low-phosphorus and zero-excess-sludge MBR claims, define the prior art a new fouling-control or aeration-energy filing is most likely to collide with.
Search the full record setWatch the under-claimed IPC branches before they fill in
C12M, B01F, C12P, B01J and G01N each sit under 6% of the 541 records — thin enough now that a specific, well-drafted claim in bioreactor apparatus integration or real-time fouling sensing has room most core water-treatment claims no longer offer.
Explore white space with Patsnap EurekaModel whether the 2018-peak decline is structural or cyclical
Recent-year momentum is flat at zero across every leading assignee tracked, which could mean the core claim space is saturated, or that publication lag is masking activity not yet visible in this cut-off — worth revisiting once 2025-2026 data settles.
Track filing trends over timeCommon questions about MBR patents
Within this 541-record scope, one assignee leads with 54 records, well ahead of the fifth-place assignee at 19. The top five assignees combined hold 30.5% of all records, and the top ten hold 40.5%, which means the rest of the field — a further 100 companies in the ranked list — splits the remaining 60% among a long tail of smaller filers. This is a concentrated-at-the-top field with plenty of room beneath it, rather than one dominated end to end by a handful of players.
Filing peaked in 2018 at 36 records and had fallen to 18 by the 2022 midpoint, roughly half the peak, with no later rebound visible in the data through the most recent complete years. Every leading assignee tracked for recent-year momentum shows zero filings in the latest year, reinforcing the slowdown. Publication lag of roughly 18 months means the final year or two of any trend chart understates true activity, but that lag alone does not account for a multi-year decline that started years before the data cut-off.
US10442712B2, assigned to Nanjing University and granted in 2019, covers an MBR architecture built around integrated fouling control — combining a reactor wall, membrane element, collecting pipes, vacuum table, suction pump, cleaning unit, air compressor and aeration components into one system designed to avoid chemical cleaning agents. It is a useful reference point for anyone drafting a fouling-control claim, since it defines a specific hardware combination rather than a broad method, meaning filings built around different hardware integration or alternative fouling-mitigation mechanisms have room to avoid direct overlap. Any new filing in this space should still be checked against it and the other highly-cited records in this scope during drafting.
C02F (water and wastewater treatment) appears on 97.6% of the 541 records in this scope, which is expected given the search terms, and B01D (separation processes including filtration) appears on 40.5%, marking it as the strongest secondary claim area. Everything else — C12M bioreactor apparatus, B01F mixing, C01B inorganic compounds, C12P fermentation, B01J catalysis and G01N analysis — sits at or under 5.5% of records each. A thorough clearance search needs to cover both C02F and B01D at minimum, with the smaller classes worth checking depending on the specific claim being drafted.
The IPC subclasses sitting under 6% of the 541 records — C12M (bioreactor apparatus), B01F (mixing/aeration hardware), C12P (fermentation-based pre-treatment), B01J (catalytic surfaces) and G01N (analytical/sensing methods) — are comparatively thin relative to the near-universal C02F and the dense B01D. That does not guarantee an easy grant, since high filing density elsewhere means the core problem space is well mapped, but it does mean fewer prior filings to design around in those specific branches. A claim drafted around real-time fouling sensing or catalytic anti-fouling surfaces, for instance, has more open ground than one drafted around basic membrane separation hardware.
Research Membrane Bioreactor (MBR) Systems in depth with Eureka
Go past this page: query the whole membrane bioreactor (mbr) systems corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.